Skip to content
DataLookout
Menu

NCT07907653

Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pathological Complete Response or Minimal Residual Disease (pCR/MRD) Rate
Timeframe: At postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation; qualifying surgery within 56 days after the actual end of neoadjuvant treatment).

Secondary (20)

Metastasis-Free Survival (MFS)
Event-Free Survival (EFS)
Time to Distant Metastasis
Time to First Subsequent Anticancer Therapy
Biochemical Recurrence-Free Survival (bRFS)
Show 15 moreShow less
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of Participants With Grade 3 or Higher Adverse Events
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of Participants With Adverse Events Leading to Study Drug Interruption, Dose Modification, or Permanent Discontinuation
Percentage of Participants With Treatment-Related Deaths
Serum Prostate-Specific Antigen (PSA) Level at the End of Neoadjuvant Treatment
Serum Prostate-Specific Antigen (PSA) Levels After Radical Prostatectomy and During Adjuvant Treatment
Pathological Primary Tumor Stage (ypT) After Neoadjuvant Treatment
Pathological Regional Lymph Node Stage (ypN) After Neoadjuvant Treatment
Composite Pathological Downstaging Rate (T and/or N)
Positive Surgical Margin Rate
Objective Response Rate (ORR) at the End of Neoadjuvant Treatment
Radical Prostatectomy Rate
Rate of Radical Prostatectomy Delay Due to Treatment-Related Adverse Events
Incidence and Severity of Postoperative Complications

Arms and interventions

Perioperative Deutenzalutamide Plus Androgen Deprivation Therapy With Neoadjuvant DocetaxelExperimental

Neoadjuvant treatment: deutenzalutamide 80 mg orally once daily plus androgen deprivation therapy (ADT) for 24 weeks, with docetaxel 60 mg/m2 intravenously every 3 weeks for 6 cycles. Prednisone acetate 5 mg orally twice daily is given during docetaxel treatment, with subsequent tapering/discontinuation according to the protocol. When medically appropriate, participants undergo radical prostatectomy with pelvic lymph node dissection approximately 2 weeks after neoadjuvant treatment. After adequate postoperative recovery, deutenzalutamide is resumed at the last tolerated dose with ADT for 24 weeks, starting approximately 4 weeks after surgery. No postoperative docetaxel is given. ADT continues throughout for a total of at least 13 months. Dose modifications and treatment interruptions follow the protocol.

Drugs: Deutenzalutamide, Docetaxel, ADT

Sites

1 site in 1 country

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China